Skip to main content
SpringerLink
Log in

Consider old and new approaches when treating dyslipidaemia

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Statins are still the cornerstone of lipid-lowering therapy, whether it is to decrease low-density lipoprotein-cholesterol (LDL-C) or triglycerides (TGs). Ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors and bile acid sequestrants are typical add-on options for additional LDL lowering; omega-3 fatty acids and fibrates are add-on options for additional TG lowering. Newer approaches for consideration include bempedoic acid and inclisiran for LDL lowering and evinacumab and volanesorsen for TG lowering. In addition to pharmacotherapy, lifestyle changes such as maintaining a healthy diet, should be encouraged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Angell SY, McConnell MV, Anderson CAM, et al. The American Heart Association 2030 impact goal: a presidential advisory from the American Heart Association. Circulation. 2020;141(9):e120–38.

    Article  Google Scholar 

  2. Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395(10226):785–94.

    Article  Google Scholar 

  3. Roger VL, Sidney S, Fairchild AL. Recommendations for cardiovascular health and disease surveillance for 2030 and beyond: a policy statement from the American Heart Association. Circulation. 2020;141(9):e104–19.

    Article  Google Scholar 

  4. Francula-Zaninovic S, Nola IA. Management of measurable variable cardiovascular disease’ risk factors. Curr Cardiol Rev. 2018;14(3):153–63.

    Article  Google Scholar 

  5. Grundy SM, Feingold KR. Guidelines for the management of high blood cholesterol. In: Feingold KR, Anawalt B, Boyce A, et al, editors. Endotext. South Dartmouth, MA: MDText.com, Inc; 2000.

  6. Ferraro RA, Leucker T, Martin SS, et al. Contemporary management of dyslipidemia. Drugs. 2022;82(5):559–76.

    Article  CAS  Google Scholar 

  7. Grundy SM, Stone NJ, Bailey AL. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143.

    PubMed  Google Scholar 

  8. Mach F, Baigent C, Catapano AL. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–88.

    Article  Google Scholar 

  9. National Kidney Foundation. What you should know about blood lipids. https://www.kidney.org/. Accessed 23 July 2022.

  10. American Heart Association. Cholesterol 101: an introduction. 2020. https://www.heart.org/. Accessed 23 July 2022.

  11. Harvard Health Publishing. How it's made: cholesterol production in your body. 2017. https://www.health.harvard.edu/heart-health/how-its-made-cholesterol-production-in-your-body. Accessed 23 July 2022.

  12. Feldman F, Koudoufio M, Desjardins Y, et al. Efficacy of polyphenols in the management of dyslipidemia: a focus on clinical studies. Nutrients. 2021;13(2):672.

    Article  CAS  Google Scholar 

  13. Stone NJ, Blumenthal RS, Lloyd-Jones D, et al. Comparing primary prevention recommendations. Circulation. 2020;141(14):1117–20.

    Article  Google Scholar 

  14. SCORE2 working group and ESC cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54.

    Article  Google Scholar 

  15. Bartlomiejczyk MA, Penson P, Banach M. Worldwide dyslipidemia guidelines. Curr Cardiovasc Risk Rep. 2019. https://doi.org/10.1007/s12170-019-0597-x.

  16. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):P1267–78.

    Article  Google Scholar 

  17. Cannon CP, Blazing MA, Giugliano RP. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.

    Article  CAS  Google Scholar 

  18. Sabatine MS, Giugliano RP, Keech AC. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.

    Article  CAS  Google Scholar 

  19. Szarek M, White HD, Schwartz GG. Alirocumab reduces total nonfatal cardiovascular and fatal events. J Am Coll Cardiol. 2019;73(4):387–96.

    Article  CAS  Google Scholar 

  20. Baigent C, Landray MJ, Reith C. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):P2181–92.

    Article  Google Scholar 

  21. Schwartz GG, Steg PG, Szarek M. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Esther S. Kim & Arnold Lee

Authors
  1. Esther S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnold Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold Lee.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

E. S. Kim, a contracted employee of Adis International Ltd/Springer Nature, and A. Lee, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, E.S., Lee, A. Consider old and new approaches when treating dyslipidaemia. Drugs Ther Perspect 38, 437–442 (2022). https://doi.org/10.1007/s40267-022-00947-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-022-00947-1

Search

Navigation